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ABSTRACT
Objectives: To increase the frequency and quality of
screening for the metabolic syndrome in people
prescribed continuing antipsychotic medication.
Design: An audit-based, quality improvement
programme (QIP) with customised feedback to
participating mental health services after each audit,
including benchmarked data on their relative and
absolute performance against an evidence-based
practice standard and the provision of bespoke change
interventions.
Setting: Adult, assertive outreach, community
psychiatric services in the UK.
Participants: 6 audits were conducted between 2006
and 2012. 21 mental health Trusts participated in the
baseline audit in 2006, submitting data on screening
for 1966 patients, while 32 Trusts participated in the
2012 audit, submitting data on 1591 patients.
Results: Over the 6 years of the programme, there
was a statistically significant increase in the proportion
of patients for whom measures for all 4 aspects of the
metabolic syndrome had been documented in the
clinical records in the previous year, from just over 1 in
10 patients in 2006 to just over 1 in 3 by 2012. The
proportion of patients with no evidence of any
screening fell from almost ½ to 1 in 7 patients over the
same period.
Conclusions: The findings suggest that audit-based
QIPs can help improve clinical practice in relation to
physical healthcare screening. Nevertheless, they also
reveal that only a minority of community psychiatric
patients prescribed antipsychotic medication is
screened for the metabolic syndrome in accordance
with best practice recommendations, and therefore
potentially remediable causes of poor physical health
remain undetected and untreated.
INTRODUCTION
People with schizophrenia have an excess
mortality, 2 to 3 times higher than the general
population; life expectancy is shortened by
15–20 years.1 This differential mortality gap
appears to have increased over recent
decades.2 3 Approximately 60% of this excess
mortality is due to physical illness.3 This may
be partly because, for various reasons, phys-
ical illnesses in people with schizophrenia
may be diagnosed late and not optimally
treated. Other reasons are associated with the
psychotic illness itself as well as illness-related
factors such as physical inactivity, cigarette
smoking, excess alcohol consumption and
poor diet. However, treatment with anti-
psychotic medication is also a contributory
factor, not least because of the metabolic side
effects, including weight gain.3 4
Hypertension, central obesity, raised
fasting glucose and dyslipidaemia, when clus-
tered together, are highly predictive of
Strengths and limitations of this study
▪ The findings regarding screening are based on
self-report data from secondary care mental
health services, and relate only to measures and
assessments that were documented in the clin-
ical records.
▪ The generalisability of these findings rests on the
large national sample sizes; at each audit, each
participating clinical team was asked to submit
screening data for all eligible patients on their
caseload, so systematic bias in the selection of
cases is unlikely.
▪ Information was not systematically collected
from participating mental health services on the
generation and implementation of local action
plans to tackle areas where practice fell short of
the standard or the use of the bespoke change
interventions.
▪ The extent to which the improvement seen in
physical healthcare monitoring in patients pre-
scribed continuing antipsychotic medication can
be attributed to the participation of services in
the quality improvement programme is uncertain
as there were other national initiatives raising
awareness of the need for such monitoring over
the 6-year period.
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cardiovascular disease and type 2 diabetes. Individuals
who have at least three of these risk factors have been
described as having metabolic syndrome (MS). MS is
relatively common in people on long-term antipsychotic
treatment, with a prevalence varying from 6% to over
60%.5–8 All four aspects of the MS are potentially
remediable. Antipsychotic-induced weight gain and the
metabolic side effects can be difﬁcult to manage, but
there is a range of possible interventions. These include
advice on lifestyle, diet and exercise,9 switching to an
antipsychotic with a lower liability for such
adverse effects,10 augmentation of antipsychotic medica-
tion with drugs such as metformin or topiramate, and
augmentation of clozapine and possibly olanzapine with
aripiprazole.11–13
There is a consensus across evidence-based guidelines
that patients on continuing antipsychotic medication
should receive regular metabolic monitoring and
adequate treatment of any cardiometabolic risk factors
identiﬁed. In routine clinical practice, such monitoring
tends to fall well short of relevant guideline recommen-
dations.14 15 This paper reports on an audit-based,
quality improvement programme (QIP) in the UK tar-
geted at screening for the MS in community psychiatric
patients on continuing antipsychotic medication.
METHODS
The Prescribing Observatory for Mental Health
(POMH-UK)16 invited all National Health Service
(NHS) Trusts and other private or charitable healthcare
organisations (hereafter referred to as Trusts) in the UK
providing specialist mental health services to participate
in an audit-based QIP focusing on screening for the MS
in people prescribed antipsychotic medication under
the care of assertive outreach community psychiatric ser-
vices. All services were self-selected in that they chose to
participate, and each participating clinical team was
asked to review the clinical records of every patient
under their care who was prescribed antipsychotic medi-
cation at the time of the audit.
The practice standard for audit was that all patients
prescribed continuing antipsychotic medication should
have their blood pressure, body mass index (BMI; or
other measure of obesity), blood glucose (or glycated
hemoglobin (HbA1c)) and lipids measured at least once
a year. Annual screening was considered the minimum
acceptable practice; most relevant national guidelines
recommend more frequent screening of some or all of
these measures depending on the drug prescribed or a
patient’s demographic or clinical characteristics. The
audit tool was developed by the POMH-UK team,
advised by an expert steering group and staff from
mental health NHS Trusts attending POMH-UK regional
workshops. Clinical audits were conducted in 2006
(baseline) and 2007 (reaudit), and subsequently, supple-
mentary audits were carried out in 2008, 2009, 2010 and
2012. At each audit, the data collected on each patient
included the following: (1) demographic data: age,
gender and ethnicity; (2) clinical data: International
Classiﬁcation of Diseases 10th Revision (ICD-10) mental
health diagnoses, known diagnosis of diabetes, hyperten-
sion or disturbed plasma lipid proﬁle; (3) medication
information: details of the antipsychotic medication cur-
rently prescribed including whether it was a ﬁrst-
generation (FGA) or second-generation (SGA) anti-
psychotic drug and whether it constituted a high-dose
prescription (high dose was deﬁned as an antipsychotic
drug prescribed at a daily dose above the maximum
recommended in the British National Formulary
(BNF)17 or, if a patient were prescribed more than one
antipsychotic, where the cumulative percentage of the
BNF maximum dose for the drugs was more than
100%), other medication prescribed; and (4) monitor-
ing data: whether there was documentation in the clin-
ical records that there had been assessment of the four
aspects of the MS—blood pressure, obesity status (BMI
or weight and height or waist circumference or waist-hip
ratio), blood glucose (random or fasting blood glucose,
HbA1c or glucose tolerance test) and plasma lipid
proﬁle (high-density lipoprotein and low-density lipopro-
tein and/or total cholesterol) in the previous year, as
well as whether the documented tests had been carried
out by a mental health team, an acute general hospital
team or in primary care.
After each audit, customised reports were sent to each
participating Trust. The ﬁrst section of the report sum-
marised the national data while the second provided
each Trust with their own performance data, bench-
marked anonymously against the performance of the
other participating Trusts, thus allowing review of both
relative and absolute performance against the standard
for screening of the four MS aspects. The ﬁnal section
of the report allowed for comparison of performance
across the individual clinical teams within a Trust.
Change intervention
In 2006, a questionnaire was sent out to all participating
Trusts to gather information on potential barriers to
screening as well as possible facilitating factors. The ﬁnd-
ings of the questionnaire have been reported else-
where14 and, along with the analysis of the data
collected in the baseline audit, informed the develop-
ment of change interventions. The main one was a
poster indicating the normal ranges for test results for
the four aspects of the MS, the range of borderline high
results that would warrant lifestyle advice and/or add-
itional monitoring, and the threshold levels of elevated
results that should prompt referral for review by a
general practitioner or medical team. This poster was
made available to all participating Trusts to support their
local action plans, prompted by the ﬁndings in their
individual audit reports. In addition, a lifestyle manage-
ment pack was developed, which provided guidance and
resources for staff and service users relating to aspects of
physical health such as diet, physical exercise and
2 Barnes TRE, et al. BMJ Open 2015;5:e007633. doi:10.1136/bmjopen-2015-007633
Open Access
smoking cessation. There was also an intervention
designed for service users: a physical health check
reminder card.
Statistical analysis
Analysis of the data was performed using the computer
software, SPSS (IBM SPSS statistics V.21, Chicago,
Illinois, USA). Simple descriptive statistics were used to
examine the demographic and clinical characteristics of
the patient sample and describe prescribing practice,
including performance against the clinical practice
standard.
To evaluate the trend in outcome over the duration of
the programme, the data analysis used three outcome
variables, all of which are related to the practice stand-
ard for the clinical audits. These three variables, mea-
sured at the individual patient level, were: no evidence
of MS screening in the past year; some evidence of MS
screening in the past year and documentation in the
past year of a test result for all four aspects of MS. A
feature of the data was that different combinations of
mental health Trusts took part at each clinical audit, and
there was variability in outcomes between Trusts.
Therefore, the analysis needed to take account of varia-
tions in participating Trusts over time. Given the data
structure and the binary nature of the outcomes, a
multilevel logistic regression was performed. Two-level
models were used with individual patients nested within
Trusts. To allow for an easier interpretation of the
results, a consistent trend over time was assumed by
using a linear term for year of audit.
Further, a binary logistic regression was performed on
data from the 2012 sample to examine the clinical
factors associated with whether or not patients had evi-
dence of all four measurements of physical health,
namely documented results for blood pressure, obesity
status, blood glucose and lipid proﬁle, in the past year,
or three or fewer measures. A logistic regression was per-
formed in two stages. First, the separate association
between each variable and the outcome was examined
in a series of univariable analyses. The second stage
jointly examined associations with the outcome in a mul-
tivariable analysis. To simplify the ﬁnal regression
model, a backwards selection procedure was performed
to retain only the statistically signiﬁcant variables. This
involves omitting non-signiﬁcant variables, one at a time,
until only the signiﬁcant variables remain.
RESULTS
For each audit between 2006 and 2012, the number of
participating Trusts and the size of the total national
sample of patients, cared for within assertive outreach
teams, are shown in table 1. The demographic and clin-
ical characteristics of the 1591 community patients in
the 2012 national sample are shown in table 2.
Table 1 shows the proportion of the sample for whom
there was no documented evidence in their clinical
records of screening for any aspect of the MS in the pre-
vious year, the proportion who had documented evi-
dence of partial screening (mention of review of any of
the four aspects of the MS and/or documentation of up
to three relevant test results) and those who had docu-
mented test results for all four aspects. High-dose anti-
psychotic medication was prescribed for 8% of the
national sample in 2012, while the respective ﬁgure for
combined antipsychotics was 19%.
Figure 1 shows the proportion of patients in each of
these clinical audits for whom test results for obesity,
blood pressure, plasma glucose and plasma lipid proﬁle
were documented in the clinical records during the pre-
vious year. A higher percentage indicates that practice
was closer to the audit standard for that aspect of the
MS during the past year. In 2006, the proportions of
patients in the national sample with a result or measure
in their clinical records for blood pressure, obesity/BMI,
blood pressure, plasma glucose and lipid proﬁle were
17%, 26%, 28% and 22%, respectively. By 2012, the cor-
responding ﬁgures were 58%, 59%, 52% and 50%. The
data in ﬁgure 2 reveal that, in the 2012 supplementary
audit, the majority of the assessments documented in
the clinical records in mental health services had been
undertaken by mental health teams rather than by
primary care.
Table 1 shows the proportion of the patients in the
national samples from 2006 to 2012 who were screened
for all four aspects of the MS. At each audit, from 2006
to 2012, there was marked variation across the participat-
ing Trusts. In 2012, the proportion of patients in Trust
samples with a test result for all four MS aspects varied
Table 1 Level of documented screening for the metabolic syndrome (MS) in the total national sample at each audit from
2006 to 2012
Clinical audit
2006 2007 2008 2009 2010 2012
Number of participating Trusts 21 21 13 21 29 32
Number of participating clinical teams 48 35 28 56 76 100
Number of patients in sample 1966 1516 1035 2522 3058 1591
No evidence of MS screening 46% 25% 31% 28% 27% 14%
Some evidence of MS screening 43% 52% 50% 50% 49% 52%
Test result documented for all four aspects of MS 11% 23% 18% 22% 24% 34%
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from 0% to 70%. The proportion of the national sample
with no evidence of screening of any aspect of the MS
over the previous year fell during the course of the QIP,
from 46% in 2006 to 14% in 2012.
A multilevel logistic regression analysis was conducted
to examine the trend in outcome of MS screening per-
formance over the 6 years. The results are reported in
table 3 in the form of ORs, indicating the relative
change in the odds of an outcome occurring for a
1-year increase in time. Corresponding CIs for the ORs
are also reported, along with p values indicating the sig-
niﬁcance of the results. The results show that the odds
of ‘no evidence’ of screening occurring decreased by
around a quarter for each year of the programme. Over
the same period, there was an increase in the propor-
tion of patients with some evidence of MS screening and
of those for whom all four aspects of the MS had been
documented in the previous year. The increase in the
proportion of patients with some evidence of screening
was smaller: the odds of this level of screening occurring
increased by 6% a year. There was a larger increase in
the proportion with documentation of all four aspects of
MS, with the odds of this outcome occurring increasing
by just over a quarter each year.
To explore which clinical factors might be related to
the likelihood of full screening, we examined the clinical
characteristics of those patients in the 2012 audit sample
with documented results for all four MS variables within
the past year. A series of univariable logistic regression
analyses were conducted to examine the separate associ-
ation between each variable and having all four MS mea-
surements documented in a patient’s clinical records
within the past year. The variables tested were age,
gender, ethnicity, a known diagnosis of diabetes, a
known diagnosis of hypertension, a known diagnosis of
dyslipidaemia, prescription of a depot/long-acting anti-
psychotic preparation as the only antipsychotic medica-
tion, prescription of a combination of depot/long-acting
antipsychotic preparation and oral antipsychotic, pre-
scription of an FGA oral antipsychotic, prescription of a
FGA depot antipsychotic, prescription of clozapine, pre-
scription of a SGA oral antipsychotic other than cloza-
pine, prescription of more than one antipsychotic drug
and prescription of high-dose antipsychotic medication.
Those variables with a signiﬁcant association with having
all MS measurements documented were examined in a
multivariable analysis. A backwards selection procedure
was used to retain only the statistically signiﬁcant vari-
ables, and the ﬁnal model resulting from this process is
summarised in table 4.
The multivariable results suggested that being pre-
scribed a depot/long-acting antipsychotic preparation as
the only antipsychotic medication, a known diagnosis of
diabetes and a known diagnosis of dyslipidaemia were all
independently associated with having all MS measure-
ments documented. As in the univariable analyses,
patients with diabetes and dyslipidaemia were more
likely to have all four measurements in their clinical
records, while patients receiving only a depot anti-
psychotic were less likely to have all four measurements
documented. After adjusting for the effects of these
three variables, there were no additional effects of ethni-
city, FGA oral medication or known diagnosis of hyper-
tension, all of which were statistically signiﬁcant in the
univariable analyses.
DISCUSSION
The National Institute for Health and Care Excellence
(NICE) psychosis and schizophrenia guideline published
in 201418 speciﬁcally recommended that appropriate
physical health checks, including the MS variables
addressed in this QIP, should take place annually, which
is in line with the practice standard we had audited
against since 2006. Over the 6 years of the POMH-UK
QIP, the audits against this standard, in samples of
people prescribed antipsychotic medication under the
Table 2 Demographic and clinical characteristics of the
2012 national audit sample
Total national
sample
N=1591
Gender: % male/% female 67/33
Age (years): mean (SD) 43 (11)
Ethnicity (%)
White/White British 69
Black/Black British 12
Asian/Asian British 9
Mixed/other 5
Not collected 4
Not stated/declined <1
Psychiatric diagnosis, ICD-10 code (%)
F00-F09: organic, including
symptomatic, mental disorders
2
F10-F19: mental and behavioural
disorders due to psychoactive
substance use
1
F20–29: schizophrenia, schizotypal and
delusional disorders
72
F30–39: mood (affective) disorders 13
F40–48: neurotic, stress-related and
somatoform disorders
1
F50–59: behavioural syndromes
associated with physiological
disturbances and physical factors
<1
F60–69: disorders of adult personality
and behaviour
6
F70–79: mental retardation 2
F80–89: disorders of psychological
development
<1
F90–98: behavioural and emotional
disorders with onset usually occurring
in childhood and adolescence
<1
F99: unspecified mental disorder <1
Not known 2
ICD-10, International Classification of Diseases 10th Revision.
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care of assertive outreach services, revealed an improve-
ment in the frequency and breadth of screening for the
MS. The successive national audit samples show an
increase in the proportion of patients for whom there
were documented measures for all four aspects of the
MS in the previous year, from just over 1 in 10 patients
Figure 1 Proportion of patients
in the total national sample with
documented metabolic syndrome
measures in their clinical records:
2006–2012 (BMI, body mass
index).
Figure 2 Clinical service/team
that conducted metabolic
syndrome tests in the 2012 audit
(BMI, body mass index; GP,
general practitioner).
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in 2006 to just over 1 in 3 in 2012. An initial increase in
screening from the baseline audit in 2006 to reaudit in
2007, with a doubling of the proportion of patients with
evidence of full screening, with documentation of all
four aspects of the MS, was maintained over the subse-
quent audits, further improvement not being evident
until the 2012 supplementary audit. By 2012, only 14%
of the national sample had no evidence of any screen-
ing, compared with 46% in 2006.
The generalisability of these ﬁndings rests on the
large national sample sizes. For the majority of the
audits, a third or more of all the mental Trusts in
England participated, and in 2012, it was well over half.
For each audit, participating clinical services were asked
to submit screening data on all eligible patients on their
caseload, so systematic bias in the selection of cases is
unlikely. However, when interpreting the data collected,
a further issue is whether any change in the level of
screening seen over time might be partly attributable to
variation in the proportion of the total patient sample
contributed by each of the Trusts at each audit. When
addressing the changes in screening practice seen
between the 2006 baseline audit and the 2007 reaudit,
we performed a multilevel logistic regression to correct
for such differences between Trusts. The results indi-
cated that, for all four MS measures, there was a statistic-
ally signiﬁcant difference between baseline and reaudit,
with no apparent bias introduced into the ﬁndings by
the variation in the number of Trusts participating on
the two occasions.19 The results of a multilevel logistic
regression analysis of the trend in MS screening data
across all six audits, which also took account of varia-
tions in participating Trusts over time, provided evidence
of a statistically signiﬁcant fall over the course of the pro-
gramme in the proportion of patients who had no evi-
dence of MS screening over time and a signiﬁcant
increase in the proportion of patients with partial or full
MS screening.
As in all the audits conducted as part of this QIP, vari-
ation in current screening practice across the participat-
ing Trusts in the 2012 supplementary audit was marked.
For those Trusts that had taken part in the previous
audits, the level of screening for the MS had also varied
over time. During the QIP, we had suggested to Trusts
that when they developed local action plans to address
any shortfall between their prescribing performance and
the practice standard, they might wish to take account of
possible inﬂuences, such as the degree to which local
strategies to ensure screening had already been imple-
mented, whether they had selected different patient
samples or even different assertive outreach services to
participate at different stages, and whether there had
been any relevant changes in stafﬁng, caseload or
service delivery. We did not systematically collect infor-
mation from the participating mental health services
regarding reﬂection on their practice in the light of the
benchmarked performance data provided, whether they
had generated and implemented local action plans to
tackle areas where practice fell short of the standard or
whether they had used any of the change interventions
provided. However, there is evidence from published
audit reports and Trust quality accounts that review of
the POMH audit data stimulated such activity.20–26
The extent to which the improvement seen in the pro-
portion of patients prescribed continuing antipsychotic
medication who had physical healthcare screening over
the past year can be attributed to the QIP is uncertain as
there were other national initiatives raising awareness of
the need for such screening over the 6-year period. The
NICE schizophrenia guidelines in 2002 and 200927 28
recommended such monitoring, as did the Maudsley
Prescribing Guidelines.29 In addition, NICE issued
guidelines on cardiovascular risk assessment focusing on
modiﬁcation of blood lipids in people at high risk30 in
2008, and the Royal College of Psychiatrists published a
report on physical health and mental health31 in 2009.
In 2012, some locally developed schemes within the
Table 3 Trend in the outcome of metabolic syndrome
(MS) screening performance over the 6 years of the quality
improvement programme: results of a multilevel logistic
regression analysis
Outcome OR (95% CI)*
p
Value
No evidence of MS screening 0.73 (0.70 to 0.75) <0.001
Some evidence of MS
screening
1.06 (1.03 to 1.09) <0.001
Result documented for all
four aspects of MS
1.27 (1.23 to 1.31) <0.001
*OR represents the relative change in the odds of the outcome for
the increase in time between audits.
Table 4 Multivariable analysis of effect of potential explanatory variables on documentation of measures for all four aspects
of the metabolic syndrome in the past year (n=1591)
Variable Category OR (95% CI) p Value
Prescribed depot/long-acting antipsychotic preparation as the only
antipsychotic medication
No
Yes
1 0.62 (0.49 to 0.78) <0.001
Known diagnosis of diabetes No
Yes
1 1.52 (1.10 to 2.10) 0.01
Known diagnosis of dyslipidaemia No
Yes
1 2.13 (1.62 to 2.80) <0.001
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Commissioning for Quality and Innovation (CQUIN)
framework, a ‘pay-for-performance’ scheme, included
screening for the metabolic side effects of antipsychotic
medication as a target: whether such schemes improve
health outcomes remains unclear.32 Further, since 2004,
general practitioners in England and Wales have been
incentivised within the Quality and Outcomes
Framework (QOF)33 to offer such physical healthcare
monitoring annually for people with severe mental
illness, although this ﬁnished in 2014. In our QIP audit
in 2012, the MS screening tests documented in the clin-
ical records had been undertaken by the mental health
teams in over two-thirds of cases, although results from
primary care were available in the mental health clinical
records in a small proportion of patients. The extent to
which these tests were duplicated in primary care under
the QOF but not communicated to mental health teams
is unknown.
Despite these guidelines and initiatives and the
improvements seen over the period of the POMH-UK
QIP, the extent and frequency of screening reported by
2012 was still well below best practice recommendations.
Some of the barriers to screening in practice were iden-
tiﬁed in the early stages of the QIP14 and included
uncertainty as to whether such physical health screening
was the responsibility of the psychiatric team rather than
a primary care clinician, a lack of conﬁdence in the
interpretation of abnormal screening results and limited
access to basic equipment such as a tape measure and
weighing scales. Another possible explanation for the
relatively low level of screening is that clinicians may
target patients for the assessment of metabolic side
effects rather than routinely screen all patients pre-
scribed continuing antipsychotic medication. Analysis of
the reaudit data in 2008 revealed that those psychiatric
patients with a known diagnosis of dyslipidaemia or dia-
betes, as well as those prescribed clozapine, were being
targeted for screening in that they were more likely to
have had all four MS measures documented in the past
year. As previously noted,19 this association between
screening and clozapine treatment may reﬂect clini-
cians’ perception of the risk of metabolic side effects
with this drug as well as the opportunity for blood
samples afforded by the monitoring systems in place as
part of the prescription of the drug. The association
with diagnoses of diabetes and dyslipidaemia suggests
that such diagnoses prompt more frequent screening for
metabolic problems and/or that diabetes and dyslipidae-
mia are more likely to be detected with more frequent
screening. When the data from the 2012 sample were
analysed, known diagnoses of dyslipidaemia or diabetes
emerged again as signiﬁcant predictors of full screening,
while a patient prescribed a depot/long-acting anti-
psychotic preparation as their only antipsychotic treat-
ment was less likely to have all four MS measures
documented. Receiving only a depot antipsychotic may
be a proxy for variables which were not collected in the
audit, such as level of engagement with clinical services
or frequency of medication review, or possibly the per-
ception by clinicians that at least some of the anti-
psychotic drugs commonly prescribed as depot/
long-acting preparations have a lower liability for meta-
bolic side effects.
The POMH-UK audit-based programmes demonstrate
a workable and effective methodology for quality
improvement in the NHS and also provide Trusts with
evidence of implementation of national treatment guide-
lines into practice. Any success this particular pro-
gramme achieved may be partly attributed to the use of
a widely accepted practice standard and educational and
facilitative change interventions designed to directly
address barriers to physical healthcare screening that
had been originally identiﬁed by participating clinical
teams.14 19 The improvement in the frequency and
quality of screening for the metabolic side effects of anti-
psychotics seen over the 6 years of this POMH-UK pro-
gramme should provide more opportunities for timely,
evidence-based management when such effects are iden-
tiﬁed in individual patients. This, in turn, has the poten-
tial to enhance patient safety and long-term health
outcomes.
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this clinical purpose, and not for objective ranking of healthcare
organisations, for which they are untested and would not necessarily be
appropriate.
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